Journal of Leukemia
Open Access
ISSN: 2329-6917
ISSN: 2329-6917
Kumar Saurabh
Tanzania
Research Article
Dissecting the In Vivo Leukemogenic Potency of Bclxl
Author(s): Kumar Saurabh, Michael T Scherzer, Amy Song, Kenneth W Yip, John C Reed, Chi Li and Levi J BeverlyKumar Saurabh, Michael T Scherzer, Amy Song, Kenneth W Yip, John C Reed, Chi Li and Levi J Beverly
Overexpression of anti-apoptotic members of the BCL2 family has been found in all types of cancer. A member of the family, BCLxl (B-cell lymphoma extra-large), is known to be associated with the progression of leukemogenesis. In the present study, we focused on understanding the domains of BCLxl responsible for in vivo oncogenic potency. To this end, we utilized engineered BCLxl proteins with alternative transmembrane domains or chimeric BCLxl proteins containing domains from a less potent BCL2-like protein, BCLb. As expected, mice receiving MYC-only expressing bone marrow develop leukemia by 100 days, whereas co-expression of MYC with wild type BCLxl led to aggressive myeloid leukemia with an average latency of ~25 days. Interestingly, mice injected with bone marrow co expressing MYC and BCLxl targeted specifically to either mitochondria or ER also succumbed to leukemia with an average .. View More»
DOI:
10.4172/2329-6917.1000158